Trial Profile
Pilot Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART19) in Combination With Ibrutinib in Patients With Relapsed or Refractory CD19+ CLL or SLL
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs CTL 119 (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 05 May 2020 Status changed from active, no longer recruiting to discontinued.
- 04 Dec 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Mar 2020.
- 04 Dec 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2020.